McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
McKesson will acquire Precision Medicine Group for $2.25 billion, expanding its clinical research and drug commercialization services.
Read original at benzingaStocks · News reference
McKesson Raises FY2027 Adj EPS Guidance from $43.80-$44.60 to $44.20-$45.00 vs $44.26 Est; Sees Sales $423.601B-$439.739B vs $431.419B Est
McKesson (NYSE:MCK) raises FY2027 Adj EPS guidance from $43.80-$44.60 to $44.20-$45.00 vs $44.26 analyst estimate. sees sales of $423.601 billion-$439.739 billion vs $431.419 billion analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:12 PM
- Checked
- Aug 5, 2026, 8:12 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
McKesson To Acquire Precision Medicine Group For ~$2.25
Read original at benzingaBarclays Maintains Overweight on McKesson, Raises Price Target to $1000
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $925 to $1000.
Read original at benzingaRBC Capital Initiates Coverage On McKesson with Sector Perform Rating, Announces Price Target of $845
RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE:MCK) with a Sector Perform rating and announces Price Target of $845.
Read original at benzinga